It All Starts With the Target

With the ever-increasing competitive nature of the ADC field, target selection is a key differentiator between having a failed or successful ADC. Being able to optimally triangulate the choice of linker-payload, target and indication is vital in developing an ADC that can have the biggest impact on patients.

Given recent developments in linker-payload technologies and efficacy in low-expressed tumors, this conversation is at the forefront of mind for ADC developers.

Returning for the second year, the ADC Target Selection Summit returns to help you leverage this timely opportunity to see clinical improvement on previously validated targets, witness success on targets where previous ADCs have failed and engage novel targets.

Make sure you’re in the room when experts in target ID/validation, cancer biology and drug discovery from across the biopharma industry provide an A-Z coverage of the key considerations that ADC developers are making when it comes to target selection. Learn about how to think about the payload and target holistically, understand expression profiles, and discover how proteomic and bioinformatic technologies can propel our understanding of targets forward.

Join 80+ peers for invaluable scientific and strategic discussions dedicated to ensuring you are marrying your target and linker-payload technologies to have the biggest impact on patient outcomes.

World-Class Speaker Faculty Includes:

Sayumi Yamazoe

Senior Principal Scientist

Bristol-Myers Squibb

Christopher Shelton

Scientific Director, Tumor Cell Targeting Research Unit

GlaxoSmithKline

Anikó Pálfi

Director, Biochemistry & Cell Biology

Heidelberg Pharma Research GmbH

Robert Lutz

Chief Scientific Officer

Iksuda Therapeutics

Annette Vogl

Director, Biology & Translational Research

Tubulis GmbH